Trillium Therapeutics Welcomes Dr. Michael Moore to Board of Directors
TORONTO, Feb. 23 /PRNewswire/ - Trillium Therapeutics Inc. (TTI) announced today that Dr. Michael Moore, Chief Executive Officer of PIramed, has joined TTI's Board of Directors. "The addition of Dr. Moore to TTI's Board of Directors is another important step in the company's quest to assemble strong and well-balanced leadership that blends global industry veterans with experienced investors," explained Dr. Niclas Stiernholm, TTI's Chief Executive Officer. "We are very pleased to welcome such a seasoned biotechnology executive as Michael to the TTI team. His impressive scientific credentials, vast drug development experience, and far-reaching networks in both industry and academia, make him a superb addition to TTI's already high-quality Board." Dr. Moore is currently Chief Executive Officer and Director of PIramed Ltd, a privately held UK-based biotechnology company focused on the discovery and development of drugs targeting members of the PI3 kinase super-family. He is also an Associate Professor at the Brunel Institute of Cancer Genetics and Pharmacogenomics. Prior to joining PIramed, he held several progressive positions (1988-2003), including Chief Scientific Officer and Research Director, at Xenova Group plc, a publicly traded biotechnology company. Dr. Moore has held a series of academic appointments at Christie Hospital, Paterson Institute for Cancer Research and University of Manchester, which included a tenured Cancer Research Campaign Appointment as well an Honorary Readership in Immunology and Oncology at University of Manchester Medical School. He received his Ph.D. and D.Sc. degrees from Nottingham University and has more than 150 scientific publications. Trillium also announced that Dr. Bob Uger has been promoted to Vice President, Research & Development effective February 1, 2004. TTI, a privately held Research and Development (R&D) company, specializes in the development of innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders, graft rejection and viral hepatitis. The Company identifies therapeutic candidates with promising preclinical profiles and advances these into clinical testing, with the primary objective of demonstrating safety and efficacy in humans. The Company has two lead development candidates, a CD200 fusion protein (CD200Fc) and an Fgl2-specific monoclonal antibody (Fgl2 Mab). TTI has a variety of external R&D collaborations, including several with major pharmaceutical and biotechnology companies.
SOURCE Trillium Therapeutics Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.